Janik and colleagues[87] reported that two polycythemic patients with EPO-producing RCC obtained partial or complete response to a combination of IL-2 and interferon-α treatment, suggesting that EPO-producing RCC may be an indicator of immunotherapy response. The gene discussed is EPO; the disease is renal cell carcinoma.